Globalization and Access to Drugs - Health Economics and Drugs Series, No. 007
(1998; 97 pages) [French] [Spanish] Ver el documento en el formato PDF
Índice de contenido
Ver el documentoAcknowledgements
Ver el documentoAbbreviations and acronyms
Abrir esta carpeta y ver su contenidoPART I: GLOBALIZATION AND ACCESS TO DRUGS: IMPLICATIONS OF THE WTO/TRIPS AGREEMENT
Abrir esta carpeta y ver su contenidoPART II: PRESENTATIONS AT THE AD HOC WORKING GROUP ON THE REVISED DRUG STRATEGY HELD IN GENEVA ON 13 OCTOBER 1998
Ver el documentoOther documents in the DAP - Health Economics and Drugs Series
Ver el documentoBack cover
 

Acknowledgements

The authors acknowledge the following individuals who contributed comments and constructive suggestions to the review of this document: D. G. Barboza (Law Firm of Neviani, Borges & Beildeck, Rio de Janeiro); P. Chirac (pharmacist, la revue Prescrire, Paris); C. Correa (Professor at the University of Buenos Aires); M. Haubert (Director of the Institute of Study on Economic and Social Development at the University of Paris I); B. Remiche (Professor at the University of Louvain); as well as F.S. Antezana (Former Deputy Director-General, WHO), and P. Brudon, D. Fresle, H.V. Hogerzeil, J.D. Quick and T. Sodogandji, from the Action Programme on Essential Drugs, WHO.

The authors acknowledge the helpful comments and clarifications received from the Secretariat of the World Trade Organization.

The interest expressed by Member States, multilateral organizations and nongovernmental organizations (NGOs) is also acknowledged.

Note to the reader

This document represents an introduction to the issue and one of many contributions to the on-going process of analysing the pharmaceutical and public health implications of relevant international agreements, including trade agreements. The main text of this revised version of Globalization and access to drugs incorporates the helpful comments and clarifications received from the Secretariat of the World Trade Organization. The views expressed are solely the responsibility of the authors as with all WHO documents by named authors. This revision also contains speeches which were presented at the WHO Executive Board ad hoc working group on the Revised Drug Strategy, held in Geneva on 13 October 1998. The section on definitions and terminology has been updated. The bibliography and other reference material remain as in the original.

First edition November 1997
Second edition January 1999

© World Health Organization 1999

This document is not a formal publication of the World Health Organization (WHO), and all rights are reserved by the Organization. The document may, however, be freely reviewed, abstracted, reproduced and translated, in part or in whole, but not for sale nor for use in conjunction with commercial purposes.

The views expressed in documents by named authors are solely the responsibility of those authors.

 

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013